Skip to Content
Merck
  • INF2-mediated actin filament reorganization confers intrinsic resilience to neuronal ischemic injury.

INF2-mediated actin filament reorganization confers intrinsic resilience to neuronal ischemic injury.

Nature communications (2022-10-14)
Barbara Calabrese, Steven L Jones, Yoko Shiraishi-Yamaguchi, Michael Lingelbach, Uri Manor, Tatyana M Svitkina, Henry N Higgs, Andy Y Shih, Shelley Halpain
ABSTRACT

During early ischemic brain injury, glutamate receptor hyperactivation mediates neuronal death via osmotic cell swelling. Here we show that ischemia and excess NMDA receptor activation cause actin to rapidly and extensively reorganize within the somatodendritic compartment. Normally, F-actin is concentrated within dendritic spines. However, <5 min after bath-applied NMDA, F-actin depolymerizes within spines and polymerizes into stable filaments within the dendrite shaft and soma. A similar actinification occurs after experimental ischemia in culture, and photothrombotic stroke in mouse. Following transient NMDA incubation, actinification spontaneously reverses. Na+, Cl-, water, and Ca2+ influx, and spine F-actin depolymerization are all necessary, but not individually sufficient, for actinification, but combined they induce activation of the F-actin polymerization factor inverted formin-2 (INF2). Silencing of INF2 renders neurons vulnerable to cell death and INF2 overexpression is protective. Ischemia-induced dendritic actin reorganization is therefore an intrinsic pro-survival response that protects neurons from death induced by cell edema.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(−)-Blebbistatin, solid, synthetic
Sigma-Aldrich
C646, ≥98% (HPLC)
Sigma-Aldrich
Latrunculin A, from sea sponge, ≥85% (HPLC), waxy solid
Sigma-Aldrich
Cycloheximide solution, Ready-Made Solution, microbial, 100 mg/mL in DMSO, Suitable for cell culture
Sigma-Aldrich
Bumetanide, ≥98%
Sigma-Aldrich
Anti-NeuN Antibody, clone A60, clone A60, Chemicon®, from mouse
Sigma-Aldrich
CFTR Inhibitor II, GlyH-101, CFTR Inhibitor II, GlyH-101, CAS 328541-79-3, is a cell-permeable potent, selective and reversible open-channel blocker of CFTR (Ki = 4.3 µM in CFTR-expressing FRT cells).
Sigma-Aldrich
Anti-Actin Antibody, clone C4, ascites fluid, clone C4, Chemicon®